Le Lézard
Classified in: Health
Subject: PER

UBC APPOINTS ANTHONY LUTTENBERGER CHIEF COMMERCIAL OFFICER


Biopharmaceutical services industry veteran brings decades of experience spanning late-stage drug development, clinical trials, and post-approval commercial support to UBC.

BLUE BELL, Pa., April 30, 2024 /PRNewswire/ -- United BioSource LLC (UBC), a leading provider of evidence development solutions to the biopharmaceutical industry, today announced the appointment of Anthony Luttenberger as its new Chief Commercial Officer.

Biopharmaceutical services industry veteran brings decades of cross-functional experience to UBC.

Anthony brings extensive executive leadership and strategic sales experience, spanning the pharmaceutical product life cycle including late-stage drug development, clinical trials, and product commercialization, to UBC. He is skilled at leveraging actionable insights derived from real-world data, real-world evidence, outcomes research, robust analytics, and informatics to inform innovative program design.  Anthony will play a crucial role in supporting UBC's market position through the delivery of a comprehensive commercial strategy.

"We have created positive impact for biopharma by delivering on our commitment of uniting evidence and access," said Bekki Bracken Brown, President & Chief Executive Officer, UBC. "Anthony's growth mindset, customer engagement skills, and ability to build high-performing teams, strengthen UBC's ability to consult, design, and deliver solutions that help our customers demonstrate the safety, efficacy, and value of their treatments."

In his new role, Anthony serves as a member of UBC's Senior Leadership Team and is responsible for global sales and marketing of UBC's portfolio of evidence development, safety and risk management, and patient access services.

About UBC
United BioSource LLC (UBC) is the leading provider of evidence development solutions with expertise in uniting evidence and access. UBC helps biopharma mitigate risk, address product hurdles, and demonstrate safety, efficacy, and value under real-world conditions. Underpinned by our scientific expertise, data and analytics, and innovative technologies, we offer our customers flexible solutions generating the relevant real-world data necessary to make more informed decisions earlier, meet stakeholder requirements, and, ultimately, drive better patient outcomes. For additional information, visit www.ubc.com.

SOURCE UBC


These press releases may also interest you

at 18:05
Reality TV Star, Mollie Pearce, Backs Campaign to Tackle Inequalities in Condition That Impacts Millions of People Globally
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

at 14:06
Red Door Community Raises more than $300,000 at Their Annual Luncheon Celebrating Women Working and Living with Cancer
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...

at 14:05
Easy Eats Pandemanila brand Kalihim (Philippine Bread Rolls) recalled due to undeclared egg
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

at 13:27
Industrial Automation Market In Life Sciences Industry size is set to grow by USD 5.06 bn from 2024-2028, growing global demand for healthcare services to boost the market growth, Technavio
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

at 11:03
MODULAR ATP Study of the mCRMtm System Meets Primary Safety and Efficacy Endpoints
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...

at 08:35
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...

More news about Health...


News published on and distributed by: